Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma

August 13, 2026 updated by: M.D. Anderson Cancer Center
To learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Primary Objective:

• To determine the feasibility and turnaround of clinical WES and transcriptome sequencing

Secondary Objectives:

  • To determine the frequency of actionable DNA and RNA alterations
  • To determine the concordance of DNA and RNA alterations
  • To determine the frequency of molecularly matched therapy
  • To determine the feasibility of identifying mechanism(s) of acquired resistance with genomic profiling
  • To determine the feasibility of molecularly matched therapy to acquired resistance alterations

Exploratory Objectives:

  • To determine the feasibility of prioritizing targets with precision analytics
  • To determine clinical outcomes in patients receiving molecularly matched therapy
  • To determine the role of additional emerging diagnostic technologies

Study Type

Interventional

Enrollment (Actual)

111

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77030
        • M D Anderson Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Patient Eligibility:

Inclusion Criteria:

  1. Male/female patients who are at least 18 years of age on the day of informed consent signing.
  2. Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy.
  3. Provision of written informed consent for the study.

Exclusion Criteria:

1. None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Molecular Testing
Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.
Other: Molecular Functional Portrait
Participants will be asked to allow previously-collected tumor tissue to be used for the MF Portrait test

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Percentage of participants who have genomic test results available in <=7 days
Time Frame: through study completion an average of 1 year
through study completion an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

M.D. Anderson Cancer Center

Investigators

  • Principal Investigator: Jason Westin, MD, M.D. Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 7, 2022

Primary Completion (Estimated)

May 12, 2027

Study Completion (Estimated)

May 12, 2027

Study Registration Dates

First Submitted

July 12, 2022

First Submitted That Met QC Criteria

July 14, 2022

First Posted (Actual)

July 19, 2022

Study Record Updates

Last Update Posted (Actual)

August 14, 2026

Last Update Submitted That Met QC Criteria

August 13, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022-0396
  • NCI-2022-05783 (Other Identifier: NCI-CTRP Clinical Trials Reporting Registry)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe